Clinical Trial Update: A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia. [Phase 3]

View source ↗

Summary

A Phase 3 study evaluated the safety and tolerability of switching from oral antipsychotics to a long-acting injectable form of risperidone in patients with sch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psychotic Disorders
• Schizophrenia

Drugs mentioned

• Risperdal Consta (risperidone long-acting injectable)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia, Psychotic Disorders | Phase 3 | Status: COMPLETED